Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
DM0201贴在中国健康受试者中单次/多次给药的药代动力学、安全性及耐受性研究
[Translation] Study on the pharmacokinetics, safety and tolerability of DM0201 patch after single/multiple administration in Chinese healthy subjects
单次给药:主要目的:比较中国健康受试者单次使用DM0201贴与Lidoderm®的药代动力学特征;次要目的:比较DM0201贴与Lidoderm®在中国健康受试者中单次给药的安全性、耐受性与粘附性。多次给药:主要目的:比较中国健康受试者多次使用DM0201贴与Lidoderm®的药代动力学特征;次要目的:比较DM0201贴与Lidoderm®在中国健康受试者中多次给药的安全性、耐受性与粘附性。
[Translation] Single administration: Primary purpose: To compare the pharmacokinetic characteristics of DM0201 patch and Lidoderm® in Chinese healthy subjects after single administration; Secondary purpose: To compare the safety, tolerability and adhesion of DM0201 patch and Lidoderm® in Chinese healthy subjects after single administration. Multiple administration: Primary purpose: To compare the pharmacokinetic characteristics of DM0201 patch and Lidoderm® in Chinese healthy subjects after multiple administration; Secondary purpose: To compare the safety, tolerability and adhesion of DM0201 patch and Lidoderm® in Chinese healthy subjects after multiple administration.
100 Clinical Results associated with Demotech, Inc.
0 Patents (Medical) associated with Demotech, Inc.
100 Deals associated with Demotech, Inc.
100 Translational Medicine associated with Demotech, Inc.